Insulino-sécrétagogues et insulinothérapie : niveau de preuve et controverses

Regarding renal risk, observational studies suggest a possible deleterious effect of SU while specific medications were not studied. Conversely, the ADVANCE trial is positive for the hard renal outcome (renal replacement therapy) suggesting a beneficial impact of gliclazide LM. Insulin has not been widely studied but data still suggest a neutral effect. The level of evidence regarding SU/glinides and insulin remain rather poor.